Prof. Zifu Li
Prof. Zifu Li
Huazhong University of Science and Technology (HUST), China
Title: Hydroxyethyl starch based smart nanomedicine
Derived from waxy maize, which contains more than 95% of amylopectin, hydroxyethyl starch (HES) is therefore highly water soluble, keeps the branched structure of amylopectin, and has wide clinical use as plasma volume expander.1 HES can be categorized into various classes based on its molecular weight, mole substitution of hydroxyethyl, and substitution pattern (C2/C6 ratio).2 These parameters affect the endogenous α-amylase mediated degradation of HES in blood, thus determine the pharmacokinetics of HES, enabling convenient ways to tailor the in vivo fates of HES by simply adjusting these parameters.3 The good manufacturing practice, high water solubility, tailorability, biocompatibility, biodegradability, well defined in vivo safeties, and wide clinical applications make HES a promising drug carrier which warrants clinical translation explorations.4 In this talk, we will present our progress of HES based smart nanomedicines.5-8 We prepared a novel redox-sensitive hydroxyethyl starch-doxorubicin conjugate, HES-SS-DOX, with diameter of 19.9 ± 0.4 nm, to alleviate the side effects and improve the antitumor efficacy of DOX.5 With HES-SS-PTX, we also obtained self-assembled nanoclusters (with diameter of 150 nm), which show dual α-amylase and redox responsive properties for enhanced tumor penetration and therefore improved antitumor efficacy.6 We conjugated HES with polylactide to afford HES-PLA, which self assembles to nanoparticles with varied sizes. The large sized HES-PLA nanoparticles (with diameter 700 nm) are applied to saturate the MPS system, while the smaller ones (150 nm) are loaded with DOX for enhanced drug delivery efficiency and improved anti-tumor efficacy.7 Moreover, both cytotoxic drug, for instance DOX, and immunomodulatory, for example TGF-β receptor inhibitor, can be loaded together within HES-PLA for inhibition of insufficient chemotherapy induced metastasis.8 Our researches collectively corroborate HES would be an excellent candidate for clinical applications.
Zifu Li obtained his PhD in 2012 from the Chinese University of Hong Kong. Afterwards, he worked as a postdoctoral in University of Alberta from 2013 to 2015 and as a research scientist in Georgia Tech from 2015 to 2016. He is currently a professor in National Engineering Research Center for Nanomedicine, College of Life Science and Technology at Huazhong University of Science and Technology, Wuhan, China. He has focused on smart nanomedicine for hepatocarcinomar cancer (HCC) combinational therapy, cancer immunotherapy, mechanonanooncology.